Who is sponsoring NCT00203060?

NCT00203060 is sponsored by Teva Neuroscience, Inc..

What condition does NCT00203060 study?

NCT00203060 studies Parkinson's Disease.

What drugs are being tested in NCT00203060?

Interventions: Rasagiline Mesylate, placebo.

What is the status of NCT00203060?

NCT00203060 is currently COMPLETED.

Last reviewed 2011-04-08 · How we verify

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa

NCT00203060 Phase 3 COMPLETED

Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.

Details

Lead sponsor	Teva Neuroscience, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	404
Start date	1997-07
Completion	2000-07

Conditions

Parkinson's Disease

Interventions

Rasagiline Mesylate
placebo

Primary outcomes

The primary objective is to assess the safety and efficacy of rasagiline in PD subjects, not receiving or requiring carbidopa/levodopa therapy. The primary efficacy measure will be the change in total UPDRS score, calculated from baseline to 26 weeks. — 58 weeks